Canaccord Genuity Maintains Buy on BioNTech, Raises Price Target to $171
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Bill Maughan maintains a Buy rating on BioNTech (NASDAQ:BNTX) and raises the price target from $168 to $171.
February 20, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on BioNTech and raises the price target from $168 to $171.
The upgrade in the price target by Canaccord Genuity reflects a positive outlook on BioNTech's stock, likely due to strong performance or future growth prospects. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100